Formula Feeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere).

Trial Profile

Formula Feeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere).

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/zidovudine (Primary) ; Lopinavir/ritonavir (Primary) ; Nevirapine (Primary) ; Zidovudine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROMISE
  • Most Recent Events

    • 26 Jul 2017 Results of PROMISE 1077 BF/FF trial including (NCT01253538 and NCT01061151) related to hepatotoxicity in postpartum women initiating efavirenz presented at the 9th International AIDS Society Conference on HIV Science
    • 03 Nov 2016 Interim results (n=3529) of PROMISE trial (NCT01061151 and NCT01253538) published in the New England Journal of Medicine
    • 27 Apr 2012 Actual initiation date (April 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top